[go: up one dir, main page]

WO2012083297A3 - Vecteurs adénoviraux avec régions d'hexon modifiées - Google Patents

Vecteurs adénoviraux avec régions d'hexon modifiées Download PDF

Info

Publication number
WO2012083297A3
WO2012083297A3 PCT/US2011/065753 US2011065753W WO2012083297A3 WO 2012083297 A3 WO2012083297 A3 WO 2012083297A3 US 2011065753 W US2011065753 W US 2011065753W WO 2012083297 A3 WO2012083297 A3 WO 2012083297A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus
hexon protein
serotype
adenoviral vectors
modified hexon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/065753
Other languages
English (en)
Other versions
WO2012083297A2 (fr
Inventor
Joseph T. Bruder
Douglas E. Brough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of WO2012083297A2 publication Critical patent/WO2012083297A2/fr
Publication of WO2012083297A3 publication Critical patent/WO2012083297A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une séquence d'acide nucléique codant pour une protéine d'hexon d'adénovirus chimérique, la protéine d'hexon chimérique comprenant une première partie et une deuxième partie. La première partie comprend au moins 10 résidus d'acide aminé contigus d'un premier sérotype d'adénovirus (par exemple, la protéine d'hexon d'adénovirus de sérotype 5), facultativement avec une substitution d'acide aminé. La deuxième partie comprend (a) au moins une région hypervariable (HVR) d'une protéine d'hexon d'un adénovirus d'un deuxième sérotype d'adénovirus, ou (b) au moins une région hypervariable synthétique (HVR) qui n'est pas présente dans la protéine d'hexon de l'adénovirus de type sauvage du premier sérotype d'adénovirus.
PCT/US2011/065753 2010-12-17 2011-12-19 Vecteurs adénoviraux avec régions d'hexon modifiées Ceased WO2012083297A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424459P 2010-12-17 2010-12-17
US61/424,459 2010-12-17

Publications (2)

Publication Number Publication Date
WO2012083297A2 WO2012083297A2 (fr) 2012-06-21
WO2012083297A3 true WO2012083297A3 (fr) 2012-09-27

Family

ID=45444768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/065753 Ceased WO2012083297A2 (fr) 2010-12-17 2011-12-19 Vecteurs adénoviraux avec régions d'hexon modifiées

Country Status (1)

Country Link
WO (1) WO2012083297A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (fr) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Compositions d'adenovirus oncolytiques
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (fr) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus
CA3045892A1 (fr) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Adenovirus synthetiques ciblant une tumeur et leurs utilisations
EP3773710A4 (fr) * 2018-04-04 2022-03-16 Altimmune Inc Combinaisons de compositions vaccinales induisant des lymphocytes t et leurs utilisations
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3906038A4 (fr) 2018-11-21 2022-06-01 Mayo Foundation for Medical Education and Research Adénovirus et méthodes d'utilisation d'adénovirus
EP3911671A1 (fr) 2019-04-29 2021-11-24 Mayo Foundation for Medical Education and Research Composés multivalents se liant à pd-l1 permettant de traiter un cancer
CN110272917B (zh) * 2019-06-24 2023-08-22 江苏万戎生物医药科技有限公司 一套快速准确的三质粒溶瘤腺病毒重组包装系统Ad5MixPlus及其应用
KR20230095830A (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040509A1 (fr) * 1997-03-13 1998-09-17 Cornell Research Foundation, Inc. Proteine de manteau d'adenovirus chimere et procedes d'utilisation de celle-ci
WO2006040330A2 (fr) * 2004-10-13 2006-04-20 Crucell Holland B.V. Vecteurs adenoviraux ameliores et leurs utilisations
WO2007027860A2 (fr) * 2005-08-31 2007-03-08 Genvec, Inc. Vaccins contre la malaria a base de vecteurs adenoviraux
WO2009098492A2 (fr) * 2008-02-07 2009-08-13 Andrew Baker Modulation du tropisme adénoviral

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995016772A1 (fr) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Systeme d'expression du gene d'adenovirus
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
WO1995034671A1 (fr) 1994-06-10 1995-12-21 Genvec, Inc. Systemes de vecteurs adenoviraux et lignees cellulaires complementaires
US5962311A (en) 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
EP1445322B2 (fr) 1995-06-15 2012-06-06 Crucell Holland B.V. Systèmes d'empaquetage pour adénovirus recombinants humains destinés à la thérapie génique
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
IL124654A0 (en) 1995-11-28 1998-12-06 Genvec Inc Vectors and method for gene transfer to cells
US5871727A (en) 1995-12-08 1999-02-16 Uab Research Foundation Targeted adenovirus vectors
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
CA2291323A1 (fr) 1997-05-28 1998-12-03 Genvec, Inc. Adenovirus a ciblage alternatif
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
CA2342396A1 (fr) 1998-09-11 2000-03-23 Genvec, Inc. Adenovirus a ciblage altnernatif
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE418340T1 (de) 1999-05-06 2009-01-15 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
EP1301612A2 (fr) 2000-05-31 2003-04-16 Genvec, Inc. Methode et composition destinees au ciblage d'un vecteur adenoviral
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
AU2002327380A1 (en) 2001-07-23 2003-03-18 Genvec, Inc. Cells and methods for propagating adenoviral vectors
EP1425045A4 (fr) 2001-09-13 2004-11-10 Genvec Inc Vecteur adenoviral, systeme correspondant et procedes de fabrication et d'utilisation
WO2007073513A2 (fr) 2005-11-10 2007-06-28 Genvec, Inc. Procede de propagation de vecteurs adenoviraux codant pour des produits geniques inhibiteurs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040509A1 (fr) * 1997-03-13 1998-09-17 Cornell Research Foundation, Inc. Proteine de manteau d'adenovirus chimere et procedes d'utilisation de celle-ci
WO2006040330A2 (fr) * 2004-10-13 2006-04-20 Crucell Holland B.V. Vecteurs adenoviraux ameliores et leurs utilisations
WO2007027860A2 (fr) * 2005-08-31 2007-03-08 Genvec, Inc. Vaccins contre la malaria a base de vecteurs adenoviraux
WO2009098492A2 (fr) * 2008-02-07 2009-08-13 Andrew Baker Modulation du tropisme adénoviral

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Information on data presentations, GenVec's homepage", 1 June 2009 (2009-06-01), XP055025210, Retrieved from the Internet <URL:http://www.genvec.com/go.cfm?do=Page.View&pid=130> [retrieved on 20120420] *
BRADLEY R R ET AL: "Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple Hexon Hypervariable Regions", JOURNAL OF VIROLOGY, vol. 86, no. 2, 9 November 2011 (2011-11-09), pages 1267 - 1272, XP055025037, ISSN: 0022-538X, DOI: 10.1128/JVI.06165-11 *
BRUDER J T ET AL: "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses", PLOS ONE, vol. 7, no. 4, 1 January 2012 (2012-01-01), pages E33920 - E33920, XP055024920, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0033920 *
BRUDER J: "Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies", ORAL PRESENTATION AT THE AMERICAN SOCIETY OF GENE THERAPY (ASGT) ANNUAL MEETING, SEATTLE, MAY 30 -JUNE 3 2007, 31 May 2007 (2007-05-31), XP055025053, Retrieved from the Internet <URL:http:/http://www.genvec.com/download/2007%20ASGT%20Bruder%20Altered%20Ad5%20Hexon%20FINAL%20OUT%20Slide%20Deck.pdf> [retrieved on 20120419] *
CHEN P ET AL: "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing Ad5 Neutralizing Antibodies", POSTER PRESENTED AT THE AMERICAN SOCIETY OF TROPICAL MEDICINE & HYGIENE (ASTMH) ANNUAL MEETING, NEW ORLEANS, DECEMBER 7-11, 2008, December 2008 (2008-12-01), XP055024909, Retrieved from the Internet <URL:http://www.genvec.com/download/2008%20ASTMH%20Bruder%20Modification%20of%20Ad5%20Hexon.pdf> [retrieved on 20120418] *
MATTHEWS Q L ET AL: "HIV Antigen Incorporation within Adenovirus Hexon Hypervariable 2 for a Novel HIV Vaccine Approach", PLOS ONE, vol. 5, no. 7, 1 January 2010 (2010-01-01), pages E11815, XP055025030, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0011815 *
ROBERTS D M ET AL: "Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 441, no. 7090, 11 May 2006 (2006-05-11), pages 239 - 243, XP002385300, ISSN: 0028-0836, DOI: 10.1038/NATURE04721 *

Also Published As

Publication number Publication date
WO2012083297A2 (fr) 2012-06-21

Similar Documents

Publication Publication Date Title
WO2012083297A3 (fr) Vecteurs adénoviraux avec régions d&#39;hexon modifiées
IL277740A (en) A hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism
WO2013052811A3 (fr) Vecteurs adénoviraux et procédés d&#39;utilisation associés
IL276859A (en) Novel adeno-associated virus (AAV) vectors, AAV vectors with reduced capsid deamidation and uses thereof
WO2009061413A3 (fr) Reporteur de fusion hybride et ses utilisations
IL276860A (en) Novel adeno-associated virus (AAV) vectors, AAV vectors with reduced capsid deamidation and uses thereof
WO2006040330A3 (fr) Vecteurs adenoviraux ameliores et leurs utilisations
WO2009108274A3 (fr) Procédés et compositions pour virus adéno-associés (aav) présentant des mutations de la boucle hi
BR112014008167A2 (pt) affenadenovirus (gorilla) ou vetores adenovirais e métodos de uso
WO2008010864A3 (fr) Protéine hexon d&#39;adénovirus modifiée et ses utilisations
EA201390866A1 (ru) Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35
WO2007016150A3 (fr) Exotoxines de pseudomonas mutees a antigenicite reduite
WO2009136977A3 (fr) Adénovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
WO2006021724A3 (fr) Vecteur viral adeno-associe pour realiser du saut d&#39;exons dans un gene codant une proteine a domaines dispensables
WO2013002412A8 (fr) Initialisation de contexte en fonction d&#39;une mémoire tampon d&#39;image de décodeur
EP1899470A4 (fr) Système destiné à la production rapide de vecteurs d&#39;adénovirus recombinants exempts d&#39;adénovirus, à titre élevé et à compétence de réplication
IL221615A (en) Human anti-alpha 2 integrin antibodies, nucleic acids that encode them, and vectors, surrogate cells, assemblies and kits containing them, and their use in the treatment of medical conditions
PT2379586T (pt) Vectores adenovirais oncolíticos e respectivos métodos e utilizações
WO2008141226A3 (fr) Bactéries recombinantes comprenant des vecteurs pour l&#39;expression de séquences d&#39;acide nucléique codant des antigènes
MX384984B (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
IL286284A (en) Non-viral DNA vectors and their uses for therapeutic expression fviii
WO2009142460A3 (fr) Corps synergique fusionné anticorps-peptide
WO2012114125A3 (fr) Traitement et prévention du paludisme
WO2011159928A3 (fr) Anticorps agissant comme agonistes contre dr4
WO2007134325A3 (fr) Procédés et compositions pour la production de protéines à l&#39;aide de vecteurs adénoviraux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804894

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804894

Country of ref document: EP

Kind code of ref document: A2